Core Insights - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company will participate in the RBC Capital Markets Global Healthcare Conference on May 20-21, 2025 [1] - CorMedix's lead product, DefenCath, was approved by the FDA on November 15, 2023, and was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] Company Overview - CorMedix Inc. specializes in therapeutic products aimed at preventing and treating life-threatening conditions [2] - The company is initiating clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 [2] - CorMedix plans to develop DefenCath as a catheter lock solution for use in additional therapeutic areas [2] Investor Relations - Investor contact for CorMedix is Dan Ferry, Managing Director at LifeSci Advisors [3]

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZIVO BIOSCIENCE, INC. S-1/A 1 zivo_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on October 31, 2023 Registration No. 333-274867 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 2836 87-0699977 (Primary Standard Industrial Classification Code Number) (I. ...